Drug-coating

Other FD C colors are used in drug coatings and cosmetics. 

Yellow 5 and 6 are widely used in candies and drug coatings. Orange B is used in hot dog and sausage casings. Some people are sensitive to Yellow 5 reactions to it can be severe enough that specific labeling is required for prescription medicines that contain it. None of the other certified dyes have this special requirement. 

G. H. W. Sanders, J. Booth, and R. G. Compton, Quantitative Rate Measurement of the Hydroxide Driven Dissolution of an Enteric Drug Coating Using Atomic Force Microscopy. Langmuir 13 (1997), 3080-3083. 

Wan, L. S. C., and Lai, W. F., Factors Affecting Dmg Release from Drug-Coated Granules Prepared by Fluidized-Bed Coating, Int. J. Pharmaceutics, 72 163-174(1991)... 

Compression drug coatings, 78 707-708 Compression filters, continuous, 77 379-381... 

K. Lehmann, Mixtures of aqueous polymethacrylate dispersions for drug coating, Drugs Made in Germany 37 101-102 (1988). 

Although drug-loaded stents have shown beneficial effects on restenosis and thrombosis compared to bare stents in clinical trials and real-world practice, there are still concerns about their long-term safety and efficacy. It has been reported that clinical trials of drug-eluting stents were stopped because of increased (sub)acute thrombosis and neointimal growth or insufficient efficacy. Furthermore, increased late thrombosis has been reported, especially with cytotoxic drug-coated... 

In parallel to catheter-based delivery, stent-based approaches, such as passive stent coatings (diamond-like carbon, phosphorylcholine, and silicon carbide coatings) and immobilized drug coatings (heparin-coated stents), were evaluated for their ability to inhibit restenosis. Although animal studies demonstrated some promise, none of these technologies were clinically successful for restenosis prevention. The failure of these surface modification technologies further added to the need for the development of DES based on the principles of sustained CDD,... 

Factors that make a stent strut vulnerable, which may lead to thrombosis, jailing side branches, or breakage of the struts, include the following polymer/drug coating dissolution, incomplete apposition, stent fracture, and overlap region,... 

The potential for immune responses against biologies (hypersensitivity, anti-drug antibodies, immune complexes, etc.) is something that most stent (alone or as drug-coated stents) manufacturers have not had to consider in prior development programs. 

In a variation of this theme, the stabilizer used is albumin. This technology results in an amorphous nanoparticle form of the drug coated by albumin, and having a size of about 100-200 nm. Drugs prepared by this technology have been tested by intravenous, intra-arterial, inhalational, oral, and topical administration. In the case of i.v. paclitaxel, the albumin is said to result in an increased and prolonged intracellular availability of the drug. ... 

The three surfactants commonly used in chlorofluro-carbon (CFC)-based MDI formulations are insoluble in the CFC-replacement propellants, hydrofluoroalk-ane (HFA) 134a and HFA 227. Possible formulation alternatives involve the use of an adjuvant such as ethanol to aid dissolution of the surfactant or a novel surfactant. Several companies have investigated novel materials among which are fluorosurfactants, poly-oxyethylenes and drugs coated with surfactant. ... 

Wan ESC, Lai WE Factors affecting drug release from drug-coated granules prepared by fluidized-bed coating. Int ] Pharm 1991 72 163-174. 

Lehmann K, Dreher D. Mixtures of aqueous polymethacrylate dispersions for drug coating. Drugs Made Ger 1988 31 101-102. Beckert TE, Lehmann K, Schmidt PC. Compression of enteric coated pellets to disintegrating tablets. Int J Pharm 1996 143 13— 23. 

---